A phase II trial of pegylated interferon α-2b therapy for polycythemia vera and essential thrombocythemia-Reference-Cited by-同舟云学术

A phase II trial of pegylated interferon α-2b therapy for polycythemia vera and essential thrombocythemia

Published:2006-04-25 Issue:11 Volume:106 Page:2397-2405
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Samuelsson Jan,Hasselbalch Hans,Bruserud Oystein,Temerinac Snezana,Brandberg Yvonne,Merup Mats,Linder Olle,Bjorkholm Magnus,Pahl Heike L.,Birgegard Gunnar,

Funder

Schering-Plough Nordic Biotech

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference40 articles.

1. Polycythemia vera: the natural history of 1213 patients followed for 20 years;Gruppo Italiano Studio Polycythemia;Ann Intern Med.,1995

2. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera;Marchioli;J Clin Oncol.,2005

3. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia;Cortelazzo;J Clin Oncol.,1990

4. Polycythemia vera in young people: an analysis of 58 cases diagnosed before 40 years;Najean;Br J Haematol.,1989

5. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders;Rozman;Cancer.,1991

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Национальные клинические рекомендации по диагностике и лечению Ph-негативных миелопролиферативных новообразований (истинной полицитемии, эссенциальной тромбоцитемии, первичного миелофиброза) (редакция 2024 г.);Clinical Oncohematology;2024-07-01

2. Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature;British Journal of Haematology;2024-06-10

3. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options;Annals of Hematology;2024-03-04

4. Interferons in the treatment of myeloproliferative neoplasms;Therapeutic Advances in Hematology;2024-01

5. Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management;American Journal of Hematology;2023-06-26